{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:08:02Z","timestamp":1794071282924,"version":"4.8.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T00:00:00Z","timestamp":1699574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Shenzhen High-level Hospital Construction Fund","award":["YBH2019-260"],"award-info":[{"award-number":["YBH2019-260"]}]},{"name":"Shenzhen Key Medical Discipline Construction Fund","award":["SZXK027"],"award-info":[{"award-number":["SZXK027"]}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"crossref","award":["SZSM202011016"],"award-info":[{"award-number":["SZSM202011016"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>To compare the triage performance of HPV viral loads reflected by cycle threshold values (CtV) from two different HPV testing assays: the PCR based Cobas4800 and the isothermal amplification based AmpFire assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We used the data from a sub-study of The Chinese Multi-Center Screening Trial\u00a0and analyzed the data of the cases positive in both Cobas4800 and AmpFire assays with recorded CtV. Spearman\u2019s correlation was applied to analyze the association between CtV from AmpFire and Cobas4800 assays, as well as the correlation between CtV and the histological lesion grades. The 50th percentile of CtV was used as the cutoff to construct triage algorithms for HPV-positive cases. McNemar\u2019s test was used to analyze the differences in sensitivity and specificity for detecting CIN2\u2009+\u2009and CIN3\u2009+\u2009in different triage algorithms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Four hundred forty-six HPV positive women who had consistent HPV results from Cobas4800 and AmpFire in terms of the HPV genotype and\u00a0reported Ct values were included in the analysis. The mean CtV of hrHPV tested by Cobas4800 and AmpFire were linear correlated. Direct association were showed\u00a0between the severity of cervical lesions and the HPV viral loads reflected by CtV of hrHPV, HPV16, non-16\/18 hrHPV and A9 group from both assays. HPV16\/18 genotyping combined with low-CtV for non-16\/18 hrHPV, especially A9 group, were demonstrated to be satisfactory in the\u00a0sensitivity and specificity for detecting CIN2\u2009+\u2009or CIN3\u2009+\u2009.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ct value represented a good triage marker in both PCR-based and isothermal amplification HPV detection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-023-08737-4","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T06:02:09Z","timestamp":1699596129000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A comparative analysis of cycle threshold (Ct) values from Cobas4800 and AmpFire HPV assay for triage of women with positive hrHPV results"],"prefix":"10.1186","volume":"23","author":[{"given":"Yi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinfeng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianliu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruifang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,10]]},"reference":[{"key":"8737_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"8737_CR2","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1016\/s0140-6736(07)61416-0","volume":"370","author":"M Schiffman","year":"2007","unstructured":"Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet. 2007;370:890\u2013907. https:\/\/doi.org\/10.1016\/s0140-6736(07)61416-0.","journal-title":"Lancet"},{"key":"8737_CR3","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/s0140-6736(13)62218-7","volume":"383","author":"G Ronco","year":"2014","unstructured":"Ronco G, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383:524\u201332. https:\/\/doi.org\/10.1016\/s0140-6736(13)62218-7.","journal-title":"Lancet"},{"issue":"3","key":"8737_CR4","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/annonc\/mdp471","volume":"21","author":"M Arbyn","year":"2010","unstructured":"Arbyn M, et al. European guidelines for quality assurance in cervical cancer screening. Second edition--summary document Ann Oncol. 2010;21(3):448\u201358. https:\/\/doi.org\/10.1093\/annonc\/mdp471.","journal-title":"Second edition summary document. Ann Oncol."},{"key":"8737_CR5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1002\/ijc.31261","volume":"143","author":"K Cuschieri","year":"2018","unstructured":"Cuschieri K, et al. Eurogin roadmap 2017: Triage strategies for the management of HPV-positive women in cervical screening programs. Int J Cancer. 2018;143:735\u201345. https:\/\/doi.org\/10.1002\/ijc.31261.","journal-title":"Int J Cancer"},{"key":"8737_CR6","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ygyno.2014.12.022","volume":"136","author":"WK Huh","year":"2015","unstructured":"Huh WK, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Gynecol Oncol. 2015;136:178\u201382. https:\/\/doi.org\/10.1016\/j.ygyno.2014.12.022.","journal-title":"Gynecol Oncol"},{"key":"8737_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12907-017-0058-8","volume":"17","author":"SW S\u00f8rbye","year":"2017","unstructured":"S\u00f8rbye SW, et al. Accuracy of cervical cytology: comparison of diagnoses of 100 Pap smears read by four pathologists at three hospitals in Norway. BMC Clin Pathol. 2017;17:18. https:\/\/doi.org\/10.1186\/s12907-017-0058-8.","journal-title":"BMC Clin Pathol"},{"key":"8737_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1128\/jcm.02116-14","volume":"53","author":"M Schiffman","year":"2015","unstructured":"Schiffman M, et al. A study of genotyping for management of human papillomavirus-positive, cytology-negative cervical screening results. J Clin Microbiol. 2015;53:52\u20139. https:\/\/doi.org\/10.1128\/jcm.02116-14.","journal-title":"J Clin Microbiol"},{"key":"8737_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/lgt.0000000000000277","volume":"21","author":"H Luo","year":"2017","unstructured":"Luo H, et al. Evaluation of viral load as a triage strategy with primary high-risk human papillomavirus cervical cancer screening. J Low Genit Tract Dis. 2017;21:12\u20136. https:\/\/doi.org\/10.1097\/lgt.0000000000000277.","journal-title":"J Low Genit Tract Dis"},{"key":"8737_CR10","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s12985-018-1003-x","volume":"15","author":"W Long","year":"2018","unstructured":"Long W, et al. HPV-16, HPV-58, and HPV-33 are the most carcinogenic HPV genotypes in Southwestern China and their viral loads are associated with severity of premalignant lesions in the cervix. Virol J. 2018;15:94. https:\/\/doi.org\/10.1186\/s12985-018-1003-x.","journal-title":"Virol J"},{"key":"8737_CR11","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3760\/cma.j.issn.0253-3766.2018.06.015","volume":"40","author":"TY Li","year":"2018","unstructured":"Li TY, et al. Association between high risk human papillomavirus DNA load and cervical lesions in different infection status. Zhonghua Zhong Liu Za Zhi. 2018;40:475\u201380. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-3766.2018.06.015.","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"8737_CR12","doi-asserted-by":"publisher","unstructured":"Xu L, O\u0161trbenk Valen\u010dak A, Poljak M, Arbyn M. Evaluation and Optimization of the Clinical Accuracy of Hybribio's 14 High-Risk HPV with 16\/18 Genotyping Assay within the VALGENT-3 Framework. J Clin Microbiol. 2020;58, https:\/\/doi.org\/10.1128\/jcm.00234-20.","DOI":"10.1128\/jcm.00234-20"},{"key":"8737_CR13","doi-asserted-by":"publisher","first-page":"e296","DOI":"10.1016\/s2214-109x(19)30527-3","volume":"8","author":"L Kuhn","year":"2020","unstructured":"Kuhn L, et al. Clinical evaluation of modifications to a human papillomavirus assay to optimise its utility for cervical cancer screening in low-resource settings: a diagnostic accuracy study. Lancet Glob Health. 2020;8:e296\u2013304. https:\/\/doi.org\/10.1016\/s2214-109x(19)30527-3.","journal-title":"Lancet Glob Health"},{"key":"8737_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jviromet.2015.05.016","volume":"222","author":"ME \u00c1lvarez-Arg\u00fcelles","year":"2015","unstructured":"\u00c1lvarez-Arg\u00fcelles ME, et al. Quantification of human papilloma virus (HPV) DNA using the Cobas 4800 system in women with and without pathological alterations attributable to the virus. J Virol Methods. 2015;222:95\u2013102. https:\/\/doi.org\/10.1016\/j.jviromet.2015.05.016.","journal-title":"J Virol Methods"},{"key":"8737_CR15","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.cmi.2015.09.012","volume":"22","author":"N Jazmati","year":"2016","unstructured":"Jazmati N, Hellmich M, Li\u010danin B, Plum G, Kaasch AJ. PCR cycle threshold value predicts the course of Clostridium difficile infection. Clin Microbiol Infect. 2016;22:e7\u20138. https:\/\/doi.org\/10.1016\/j.cmi.2015.09.012.","journal-title":"Clin Microbiol Infect"},{"key":"8737_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0232107","volume":"15","author":"L Duan","year":"2020","unstructured":"Duan L, et al. The effectiveness of HPV viral load, reflected by Cobas 4800 HPV-Ct values for the triage of HPV-positive women in primary cervical cancer screening: Direct endocervical samples. PLoS ONE. 2020;15: e0232107. https:\/\/doi.org\/10.1371\/journal.pone.0232107.","journal-title":"PLoS ONE"},{"key":"8737_CR17","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1177\/0969141320943634","volume":"28","author":"F Song","year":"2021","unstructured":"Song F, et al. The effectiveness of human papillomavirus load, reflected by cycle threshold values, for the triage of HPV-positive self-samples in cervical cancer screening. J Med Screen. 2021;28:318\u201324. https:\/\/doi.org\/10.1177\/0969141320943634.","journal-title":"J Med Screen"},{"key":"8737_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13027-022-00440-4","volume":"17","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, et al. Verification of the association of the cycle threshold (Ct) values from HPV testing on Cobas4800 with the histologic grades of cervical lesions using data from two population-based cervical cancer screening trials. Infect Agent Cancer. 2022;17:27. https:\/\/doi.org\/10.1186\/s13027-022-00440-4.","journal-title":"Infect Agent Cancer"},{"key":"8737_CR19","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.jmoldx.2019.12.004","volume":"22","author":"YW Tang","year":"2020","unstructured":"Tang YW, et al. An Isothermal, multiplex amplification assay for detection and genotyping of human papillomaviruses in formalin-fixed. Paraffin-Embedded Tissues J Mol Diagn. 2020;22:419\u201328. https:\/\/doi.org\/10.1016\/j.jmoldx.2019.12.004.","journal-title":"Paraffin-Embedded Tissues J Mol Diagn"},{"key":"8737_CR20","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13027-020-00328-1","volume":"15","author":"W Zhang","year":"2020","unstructured":"Zhang W, et al. Evaluation of an isothermal amplification HPV detection assay for primary cervical cancer screening. Infect Agent Cancer. 2020;15:65. https:\/\/doi.org\/10.1186\/s13027-020-00328-1.","journal-title":"Infect Agent Cancer"},{"key":"8737_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/lgt.0000000000000577","volume":"25","author":"H Du","year":"2021","unstructured":"Du H, et al. Evaluation of Cobas HPV and SeqHPV assays in the chinese multicenter screening trial. J Low Genit Tract Dis. 2021;25:22\u20136. https:\/\/doi.org\/10.1097\/lgt.0000000000000577.","journal-title":"J Low Genit Tract Dis"},{"key":"8737_CR22","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1097\/lgt.0000000000000239","volume":"20","author":"JL Belinson","year":"2016","unstructured":"Belinson JL, Pretorius RG. A standard protocol for the colposcopy exam. J Low Genit Tract Dis. 2016;20:e61-62. https:\/\/doi.org\/10.1097\/lgt.0000000000000239.","journal-title":"J Low Genit Tract Dis"},{"key":"8737_CR23","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.1371\/journal.pmed.0050132","volume":"5","author":"E Gakidou","year":"2008","unstructured":"Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med. 2008;5:e132. https:\/\/doi.org\/10.1371\/journal.pmed.0050132.","journal-title":"PLoS Med"},{"key":"8737_CR24","doi-asserted-by":"publisher","first-page":"113840","DOI":"10.1016\/j.jviromet.2020.113840","volume":"279","author":"D Jang","year":"2020","unstructured":"Jang D, et al. Performance of AmpFire HPV assay on neck cervical lymph node aspirate and oropharyngeal samples. J Virol Methods. 2020;279:113840. https:\/\/doi.org\/10.1016\/j.jviromet.2020.113840.","journal-title":"J Virol Methods"},{"key":"8737_CR25","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2147\/ijwh.S90772","volume":"7","author":"V Fargnoli","year":"2015","unstructured":"Fargnoli V, Petignat P, Burton-Jeangros C. To what extent will women accept HPV self-sampling for cervical cancer screening? A qualitative study conducted in Switzerland. Int J Womens Health. 2015;7:883\u20138. https:\/\/doi.org\/10.2147\/ijwh.S90772.","journal-title":"Int J Womens Health"},{"key":"8737_CR26","doi-asserted-by":"publisher","first-page":"100235","DOI":"10.1016\/j.lanepe.2021.100235","volume":"11","author":"F Inturrisi","year":"2021","unstructured":"Inturrisi F, et al. Clinical performance of high-risk HPV testing on self-samples versus clinician samples in routine primary HPV screening in the Netherlands: an observational study. Lancet Reg Health Eur. 2021;11:100235. https:\/\/doi.org\/10.1016\/j.lanepe.2021.100235.","journal-title":"Lancet Reg Health Eur"},{"key":"8737_CR27","doi-asserted-by":"publisher","first-page":"Cd009069","DOI":"10.1002\/14651858.CD009069.pub3","volume":"5","author":"M Arbyn","year":"2018","unstructured":"Arbyn M, Xu L, Simoens C, Martin-Hirsch PP. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev. 2018;5:Cd009069. https:\/\/doi.org\/10.1002\/14651858.CD009069.pub3.","journal-title":"Cochrane Database Syst Rev"},{"key":"8737_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.ygyno.2017.11.016","volume":"148","author":"L Dong","year":"2018","unstructured":"Dong L, et al. Human papillomavirus viral load as a useful triage tool for non-16\/18 high-risk human papillomavirus positive women: a prospective screening cohort study. Gynecol Oncol. 2018;148:103\u201310. https:\/\/doi.org\/10.1016\/j.ygyno.2017.11.016.","journal-title":"Gynecol Oncol"},{"key":"8737_CR29","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1158\/1055-9965.Epi-19-0239","volume":"28","author":"R Adcock","year":"2019","unstructured":"Adcock R, Cuzick J, Hunt WC, McDonald RM, Wheeler CM. Role of HPV Genotype, Multiple Infections, and Viral Load on the Risk of High-Grade Cervical Neoplasia. Cancer Epidemiol Biomarkers Prev. 2019;28:1816\u201324. https:\/\/doi.org\/10.1158\/1055-9965.Epi-19-0239.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"8737_CR30","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/ijgo.13406","volume":"152","author":"Y Li","year":"2021","unstructured":"Li Y, et al. Correlation between multi-type human papillomavirus infections and viral loads and the cervical pathological grade. Int J Gynaecol Obstet. 2021;152:96\u2013102. https:\/\/doi.org\/10.1002\/ijgo.13406.","journal-title":"Int J Gynaecol Obstet"},{"key":"8737_CR31","doi-asserted-by":"publisher","first-page":"e0232117","DOI":"10.1371\/journal.pone.0232117","volume":"15","author":"L Duan","year":"2020","unstructured":"Duan L, et al. The application of BMRT-HPV viral load to secondary screening strategies for cervical cancer. PLoS One. 2020;15:e0232117. https:\/\/doi.org\/10.1371\/journal.pone.0232117.","journal-title":"PLoS One"},{"issue":"8","key":"8737_CR32","doi-asserted-by":"publisher","first-page":"5373","DOI":"10.1002\/cam4.2017","volume":"2019","author":"B Zhu","year":"2019","unstructured":"Zhu B, et al. The prevalence, trends, and geographical distribution of human papillomavirus infection in China: The pooled analysis of 1.7 million women. Cancer Med. 2019;2019(8):5373\u201385. https:\/\/doi.org\/10.1002\/cam4.2017.","journal-title":"Cancer Med."},{"key":"8737_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.jclinepi.2021.06.009","volume":"139","author":"H Du","year":"2021","unstructured":"Du H, et al. The prevalence of HR-HPV infection based on self-sampling among women in China exhibited some unique epidemiologic features. J Clin Epidemiol. 2021;139:319\u201329. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.06.009.","journal-title":"J Clin Epidemiol"},{"key":"8737_CR34","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/0969141315604863","volume":"23","author":"J Zhao","year":"2016","unstructured":"Zhao J, et al. Evaluation of The Cervista HPV A9 group In Screening Patients for Cervical Cancer. J Med Screen. 2016;23:38\u201343. https:\/\/doi.org\/10.1177\/0969141315604863.","journal-title":"J Med Screen"},{"key":"8737_CR35","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.meegid.2018.03.003","volume":"61","author":"MA Oyervides-Mu\u00f1oz","year":"2018","unstructured":"Oyervides-Mu\u00f1oz MA, et al. Understanding the HPV integration and its progression to cervical cancer. Infect Genet Evol. 2018;61:134\u201344. https:\/\/doi.org\/10.1016\/j.meegid.2018.03.003.","journal-title":"Infect Genet Evol"},{"key":"8737_CR36","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.ygyno.2021.05.014","volume":"162","author":"F Song","year":"2021","unstructured":"Song F, et al. Evaluation of p16(INK4a) immunocytology and human papillomavirus (HPV) genotyping triage after primary HPV cervical cancer screening on self-samples in China. Gynecol Oncol. 2021;162:322\u201330. https:\/\/doi.org\/10.1016\/j.ygyno.2021.05.014.","journal-title":"Gynecol Oncol"},{"key":"8737_CR37","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/jnci\/djaa105","volume":"113","author":"P Giorgi Rossi","year":"2021","unstructured":"Giorgi Rossi P, et al. p16\/ki67 and E6\/E7 mRNA Accuracy and Prognostic Value in Triaging HPV DNA-Positive Women. J Natl Cancer Inst. 2021;113:292\u2013300. https:\/\/doi.org\/10.1093\/jnci\/djaa105.","journal-title":"J Natl Cancer Inst"},{"key":"8737_CR38","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s13027-020-0278-x","volume":"15","author":"A Derbie","year":"2020","unstructured":"Derbie A, Mekonnen D, Woldeamanuel Y, Van Ostade X, Abebe T. HPV E6\/E7 mRNA test for the detection of high grade cervical intraepithelial neoplasia (CIN2+): a systematic review. Infect Agent Cancer. 2020;15:9. https:\/\/doi.org\/10.1186\/s13027-020-0278-x.","journal-title":"Infect Agent Cancer"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08737-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-023-08737-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-023-08737-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T06:03:28Z","timestamp":1699596208000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-023-08737-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,10]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["8737"],"URL":"https:\/\/doi.org\/10.1186\/s12879-023-08737-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,10]]},"assertion":[{"value":"2 June 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was approved by the Ethics Committee of the Peking University Shenzhen Hospital (IRB:PUSH2016001) and the Institutional Review Board of Cleveland Clinic (USA) (IRB:15\u20131549). All methods were carried out in accordance with the rules of the Declaration of Helsinki. The informed consent was obtained from every participant.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"783"}}